Full Press Release Details
AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP Platform
generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP platform
validation will be conducted through partnership with J. Craig Venter Institute (JCVI), a world-leading institution in genomics research
MD - October 5, 2023 - BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"),
a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development
of pharmaceuticals and biologics, today announced that it has identified multiple potential therapeutic targets, including
three novel targets, for colorectal cancer using the Company's proprietary AI-driven platform, bfLEAP . The newly identified
targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a world-leading
genomics research and innovation institution. JCVI will utilize its expertise in target validation and functional genomic screening to
further investigate the potential of these targets in colorectal cancer.
bfLEAP to interrogate pan-cancer multi-modal data from The Cancer Genome Atlas (TCGA), we were able to rapidly identify new colon
adenocarcinoma markers, yielding 14 candidates that were significantly over-expressed in tumors relative to healthy tissues, a remarkably
smaller and more actionable gene set compared to traditional differential expression analysis, which yields more than 3,000 candidates
for the same comparison. After further analyzing the 14 candidates, we were able to categorize three as novel, with no previous association
with colon adenocarcinoma in the scientific literature, and six as near novel with little existing literature documenting such an association,"
said Enrique Garc a-Rivera, Ph.D., Vice President of Artificial Intelligence for BullFrog AI.
has been extensively analyzed by scientists for more than a decade, yet in a matter of weeks, we were able to identify multiple new drug
target candidates with previously undocumented potential in colorectal cancer from this same dataset," stated Vin Singh, Chairman
and CEO of BullFrog AI. "These findings demonstrate the power and potential of our bfLEAP platform, which combines advanced
AI algorithms with rich biological data to identify novel targets for a wide range of diseases. Our platform has a remarkable ability
to detect patterns, make predictions, and identify anomalies, and it can do this with multimodal data, all while providing explanations
of the results generated from its rapid analysis. Our ability to identify novel drug targets in a complex data set represents significant
potential value for our internal programs, clients and partners."
to the American Cancer Society, colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S., excluding
skin cancers, and is the third leading cause of cancer-related deaths in the U.S. The worldwide market for colorectal cancer treatments
was valued at $11.5 billion in 2022 and is forecast to grow at a compound annual growth rate of 4.7% through 2030, according to Grand
AI is a technology-enabled drug development company that creates and analyzes networks of biological, clinical, and real-world data spanning
from early discovery to late-stage clinical trials. Through its partnerships with leading research institutions, BullFrog AI is at the
forefront of AI-driven drug development using its proprietary bfLEAP artificial intelligence platform. BullFrog AI is deploying
bfLEAP for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development,
decreasing the overall development costs by decreasing failure rates for new therapeutics.
more information visit BullFrog AI at
press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about
future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events
or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business
prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those
that use terminology such as "may," "should," "expects," "anticipates," "contemplates,"
"estimates," "believes," "plans," "projected," "predicts," "potential,"
or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider
various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially
from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press
release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ
materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other
statements made from time to time by us or our representatives might not occur.
BullFrog AI Holdings, Inc.